154 related articles for article (PubMed ID: 38573209)
1. Targeting androgen biosynthesis in prostate cancer: implications on endocrine physiology.
Kango G; Malek R; Mannuel H; Hussain A
Curr Opin Oncol; 2024 May; 36(3):195-201. PubMed ID: 38573209
[TBL] [Abstract][Full Text] [Related]
2. Nuclear receptor ERRα contributes to castration-resistant growth of prostate cancer via its regulation of intratumoral androgen biosynthesis.
Xu Z; Ma T; Zhou J; Gao W; Li Y; Yu S; Wang Y; Chan FL
Theranostics; 2020; 10(9):4201-4216. PubMed ID: 32226548
[TBL] [Abstract][Full Text] [Related]
3. Impact of circulating cholesterol levels on growth and intratumoral androgen concentration of prostate tumors.
Mostaghel EA; Solomon KR; Pelton K; Freeman MR; Montgomery RB
PLoS One; 2012; 7(1):e30062. PubMed ID: 22279565
[TBL] [Abstract][Full Text] [Related]
4. Endocrine therapy: where do we stand and where are we going?
Schröder FH
Cancer Surv; 1991; 11():177-94. PubMed ID: 1841751
[TBL] [Abstract][Full Text] [Related]
5. De novo steroid biosynthesis in human prostate cell lines and biopsies.
Sakai M; Martinez-Arguelles DB; Aprikian AG; Magliocco AM; Papadopoulos V
Prostate; 2016 May; 76(6):575-87. PubMed ID: 26841972
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.
Cai C; Chen S; Ng P; Bubley GJ; Nelson PS; Mostaghel EA; Marck B; Matsumoto AM; Simon NI; Wang H; Chen S; Balk SP
Cancer Res; 2011 Oct; 71(20):6503-13. PubMed ID: 21868758
[TBL] [Abstract][Full Text] [Related]
7. Evidence for steroidogenic potential in human prostate cell lines and tissues.
Bennett NC; Hooper JD; Lambie D; Lee CS; Yang T; Vesey DA; Samaratunga H; Johnson DW; Gobe GC
Am J Pathol; 2012 Sep; 181(3):1078-87. PubMed ID: 22796438
[TBL] [Abstract][Full Text] [Related]
8. PTEN Loss Promotes Intratumoral Androgen Synthesis and Tumor Microenvironment Remodeling via Aberrant Activation of RUNX2 in Castration-Resistant Prostate Cancer.
Yang Y; Bai Y; He Y; Zhao Y; Chen J; Ma L; Pan Y; Hinten M; Zhang J; Karnes RJ; Kohli M; Westendorf JJ; Li B; Zhu R; Huang H; Xu W
Clin Cancer Res; 2018 Feb; 24(4):834-846. PubMed ID: 29167276
[No Abstract] [Full Text] [Related]
9. Intratumoral conversion of adrenal androgen precursors drives androgen receptor-activated cell growth in prostate cancer more potently than de novo steroidogenesis.
Kumagai J; Hofland J; Erkens-Schulze S; Dits NF; Steenbergen J; Jenster G; Homma Y; de Jong FH; van Weerden WM
Prostate; 2013 Nov; 73(15):1636-50. PubMed ID: 23996639
[TBL] [Abstract][Full Text] [Related]
10. Microsatellite polymorphism of steroid hormone synthesis gene CYP11A1 is associated with advanced prostate cancer.
Kumazawa T; Tsuchiya N; Wang L; Sato K; Kamoto T; Ogawa O; Nakamura A; Kato T; Habuchi T
Int J Cancer; 2004 May; 110(1):140-4. PubMed ID: 15054879
[TBL] [Abstract][Full Text] [Related]
11. P450-dependent enzymes as targets for prostate cancer therapy.
De Coster R; Wouters W; Bruynseels J
J Steroid Biochem Mol Biol; 1996 Jan; 56(1-6 Spec No):133-43. PubMed ID: 8603034
[TBL] [Abstract][Full Text] [Related]
12. Developments in the control of testicular function.
Swerdloff RS; Wang C; Bhasin S
Baillieres Clin Endocrinol Metab; 1992 Apr; 6(2):451-83. PubMed ID: 1377467
[TBL] [Abstract][Full Text] [Related]
13. First-in-Class Small Molecule to Inhibit CYP11A1 and Steroid Hormone Biosynthesis.
Karimaa M; Riikonen R; Kettunen H; Taavitsainen P; Ramela M; Chrusciel M; Karlsson S; Rummakko P; Simola O; Wohlfahrt G; Hakulinen P; Vuorela A; Joensuu H; Utriainen T; Fizazi K; Oksala R
Mol Cancer Ther; 2022 Dec; 21(12):1765-1776. PubMed ID: 36129801
[TBL] [Abstract][Full Text] [Related]
14. Nuclear Receptor LRH-1 Functions to Promote Castration-Resistant Growth of Prostate Cancer via Its Promotion of Intratumoral Androgen Biosynthesis.
Xiao L; Wang Y; Xu K; Hu H; Xu Z; Wu D; Wang Z; You W; Ng CF; Yu S; Chan FL
Cancer Res; 2018 May; 78(9):2205-2218. PubMed ID: 29438990
[TBL] [Abstract][Full Text] [Related]
15. Androgen-independent prostate cancer cells acquire the complete steroidogenic potential of synthesizing testosterone from cholesterol.
Dillard PR; Lin MF; Khan SA
Mol Cell Endocrinol; 2008 Nov; 295(1-2):115-20. PubMed ID: 18782595
[TBL] [Abstract][Full Text] [Related]
16. Modulation of AKR1C2 by curcumin decreases testosterone production in prostate cancer.
Ide H; Lu Y; Noguchi T; Muto S; Okada H; Kawato S; Horie S
Cancer Sci; 2018 Apr; 109(4):1230-1238. PubMed ID: 29369461
[TBL] [Abstract][Full Text] [Related]
17. Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer.
Hofland J; van Weerden WM; Dits NF; Steenbergen J; van Leenders GJ; Jenster G; Schröder FH; de Jong FH
Cancer Res; 2010 Feb; 70(3):1256-64. PubMed ID: 20086173
[TBL] [Abstract][Full Text] [Related]
18. Molecular pathways: Inhibiting steroid biosynthesis in prostate cancer.
Ferraldeschi R; Sharifi N; Auchus RJ; Attard G
Clin Cancer Res; 2013 Jul; 19(13):3353-9. PubMed ID: 23470964
[TBL] [Abstract][Full Text] [Related]
19. Orteronel (TAK-700), a novel non-steroidal 17,20-lyase inhibitor: effects on steroid synthesis in human and monkey adrenal cells and serum steroid levels in cynomolgus monkeys.
Yamaoka M; Hara T; Hitaka T; Kaku T; Takeuchi T; Takahashi J; Asahi S; Miki H; Tasaka A; Kusaka M
J Steroid Biochem Mol Biol; 2012 Apr; 129(3-5):115-28. PubMed ID: 22249003
[TBL] [Abstract][Full Text] [Related]
20. CYP17A1-independent production of the neurosteroid-derived 5α-pregnan-3β,6α-diol-20-one in androgen-responsive prostate cancer cell lines under serum starvation and inhibition by Abiraterone.
de Mello Martins AGG; Allegretta G; Unteregger G; Haupenthal J; Eberhard J; Hoffmann M; van der Zee JA; Junker K; Stöckle M; Müller R; Hartmann RW; Ohlmann CH
J Steroid Biochem Mol Biol; 2017 Nov; 174():183-191. PubMed ID: 28890368
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
